SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain

NCT ID: NCT01446419

Last Updated: 2016-10-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and efficacy of RF ablation using the Intracept Intraosseous Nerve Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain. This is a prospective, double-blind, randomized, sham-controlled clinical trial with an optional crossover component.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

chronic axial low back pain vertebrogenic pain Radio frequency ablation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intracept Treatment

Group Type EXPERIMENTAL

Intracept Treatment

Intervention Type DEVICE

Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.

Sham Treatment

Group Type SHAM_COMPARATOR

Sham Treatment

Intervention Type DEVICE

Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intracept Treatment

Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.

Intervention Type DEVICE

Sham Treatment

Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Skeletally mature patients age 25 - 70 years, inclusive
* Chronic lower back pain for at least six (6) months
* Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirement is as follows:

* Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy
* Supervised exercise program(minimum of 12 sessions)
* Oswestry Disability Index (ODI) at time of evaluation of at least 30 points
* Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale
* The following test indicating that the vertebral body is the source of pain:

1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1
* Understands the local language and is willing and able to follow the requirements of the protocol
* Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form

Exclusion Criteria

* Radicular pain by history or evidence of pain or neurological deficit in a dermatomal zone at or below the medial thigh.
* Previous surgery performed on the lumbar spine
* History of symptomatic spinal stenosis
* History of osteoporotic or tumor-related vertebral body compression fracture
* History of vertebral cancer or spinal metastasis
* History of spinal infection
* Metabolic bone disease (e.g. osteogenesis imperfecta)
* BMI ≥40
* Osteoporosis, defined as T score \<-2.5
* Any radiographic evidence of other important back pathology, such as:

1. Nerve root compression or severe effacement of the thecal sac that correlates with radicular pain or muscle weakness
2. Disc extrusion or disc protrusion \>5mm
3. Facet arthrosis or facet effusion at any lumbar level that correlates with clinical evidence of facet mediated low back pain
4. Spondylolisthesis 2mm or greater at any level
5. Spondylolysis at any level
* MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.
* Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain
* Demonstrates 3 or more Waddell's signs of Inorganic Behavior
* Any evidence of current systemic infection
* Uncorrected bleeding diathesis
* Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI
* Contraindication to MRI or patients who have allergies to the components of the Intracept device
* Pregnant, lactating or plan to become pregnant in next year
* Diabetes requiring daily insulin
* Current use of steroid therapy, with the exception of inhalation steroids for asthma
* Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible
* Receiving Workmen's Compensation
* Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired
* Any medical condition that impairs follow-up
* Contraindications to the proposed anesthetic protocol.
* Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin)
* Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months
* Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)
* Has a life expectancy of less than 1 year
* Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc.
* Is a prisoner
Minimum Eligible Age

25 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Relievant Medsystems, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey Fischgrund, MD

Role: PRINCIPAL_INVESTIGATOR

Michigan Orthopaedic Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Desert Institute for Spine Care

Phoenix, Arizona, United States

Site Status

SpineCare Medical Group

Daly City, California, United States

Site Status

Memorial Orthopedic Surgical Group

Long Beach, California, United States

Site Status

The Spine Institute

Santa Monica, California, United States

Site Status

Pain Center Solutions

Marietta, Georgia, United States

Site Status

Indiana Spine Group

Carmel, Indiana, United States

Site Status

Maine Medical Partners

Scarborough, Maine, United States

Site Status

Partners in Research and Educational Studies of Spinal Disorders (PressD)

Southfield, Michigan, United States

Site Status

OrthoCarolina

Charlotte, North Carolina, United States

Site Status

NeuroSpine Institute

Eugene, Oregon, United States

Site Status

Rothman Institute

Philadelphia, Pennsylvania, United States

Site Status

Seton Spine & Scoliosis Center

Austin, Texas, United States

Site Status

Virginia iSpine Physicians

Richmond, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIP 0003

Identifier Type: -

Identifier Source: org_study_id